India, Oct. 15 -- Belite Bio, Inc. (BLTE), a clinical-stage drug development company focused on degenerative retinal diseases, announced Marketing Authorisation Application (MAA) submissions to the regulatory authorities in Singapore, the United Kingdom, and Switzerland for tinlarebant to treat Stargardt disease type 1 (STGD1).
Belite submitted the three MAAs through the Access Consortium framework, a collaborative initiative involving the Health Sciences Authority (HSA), the Medicines and Healthcare products Regulatory Agency (MHRA), and Swissmedic.
Belite's lead candidate, Tinlarebant, is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that l...